Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Dec;26(6):937–938. doi: 10.1128/aac.26.6.937

Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice.

E B Fraser-Smith, D A Eppstein, Y V Marsh, T R Matthews
PMCID: PMC180056  PMID: 6335382

Abstract

The acyclic nucleoside DHPG [9-(1,3-dihydroxy-2-propoxymethyl)guanine] and recombinant human alpha-interferon of clones A/D potentiate each other's antiviral activity against a systemic infection with herpes simplex virus type 2. The effective dose at which 50% of the mice survived was lowered approximately 10-fold for DHPG when it was given in combination with a marginally effective dose of alpha-interferon and greater than 10-fold for alpha-interferon when it was given in combination with a nontherapeutic dose of DHPG.

Full text

PDF
938

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  2. Eppstein D. A., Marsh Y. V. Potent synergistic inhibition of herpes simplex virus-2 by 9-[(1, 3-dihydroxy-2-propoxy)methyl]guanine in combination with recombinant interferons. Biochem Biophys Res Commun. 1984 Apr 16;120(1):66–73. doi: 10.1016/0006-291x(84)91414-1. [DOI] [PubMed] [Google Scholar]
  3. Fraser-Smith E. B., Eppstein D. A., Marsh Y. V., Matthews T. R. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother. 1984 May;25(5):563–565. doi: 10.1128/aac.25.5.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Janz C., Wigand R. Combined interaction of antiherpes substances and interferon beta on the multiplication of herpes simplex virus. Arch Virol. 1982;73(2):135–143. doi: 10.1007/BF01314722. [DOI] [PubMed] [Google Scholar]
  5. Kramer M. J., Dennin R., Kramer C., Jones G., Connell E., Rolon N., Gruarin A., Kale R., Trown P. W. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res. 1983;3(4):425–435. doi: 10.1089/jir.1983.3.425. [DOI] [PubMed] [Google Scholar]
  6. Lee S. H., Chiu H., Rinderknecht E., Sabo W., Stebbing N. Importance of treatment regimen of interferon as an antitumor agent. Cancer Res. 1983 Sep;43(9):4172–4175. [PubMed] [Google Scholar]
  7. Levin M. J., Leary P. L. Inhibition of human herpesviruses by combination of acyclovir and human leukocyte interferon. Infect Immun. 1981 Jun;32(3):995–999. doi: 10.1128/iai.32.3.995-999.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rehberg E., Kelder B., Hoal E. G., Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem. 1982 Oct 10;257(19):11497–11502. [PubMed] [Google Scholar]
  9. Stanwick T. L., Schinazi R. F., Campbell D. E., Nahmias A. J. Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother. 1981 Apr;19(4):672–674. doi: 10.1128/aac.19.4.672. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES